Abstract | PURPOSE: EXPERIMENTAL DESIGN: A total of 91 ACC patients received capecitabine and oxaliplatin (CAPOX) as a part of a multicentre phase-III study of the Dutch Colorectal Cancer Group. Tumour response was evaluated according to RECIST, toxicity was graded using CTC, and GSTP1 Ile105Val was determined by pyrosequencing. RESULTS: Overall survival after CAPOX was similar for patients with the Ile/Ile (11.5 mo), Ile/Val (11.6 mo) and Val/Val (12.6 mo) genotypes (p=0.602). Likewise, there were no statistically significant differences in progression-free survival (p=0.252). Overall grades 3-4 toxicity was not related to genotype (p=0.313). There were no differences in any grade or grades 3-4 neurotoxicity amongst the patients who received > or =500 mg/m(2) of oxaliplatin (p-values of 0.376 and 0.772, respectively). CONCLUSIONS: The results of this study indicate that the GSTP1 genotype is not predictive for progression-free survival or overall survival in ACC patients treated with CAPOX. Moreover, overall neurotoxicity and neurotoxicity in patients receiving 500 mg/m(2) of oxaliplatin was not associated with GSTP1 genotype.
|
Authors | Dina M Kweekel, Hans Gelderblom, Ninja F Antonini, Tahar Van der Straaten, Johan W R Nortier, Cornelis J A Punt, Henk-Jan Guchelaar |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 45
Issue 4
Pg. 572-8
(Mar 2009)
ISSN: 1879-0852 [Electronic] England |
PMID | 19084393
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Codon
- Organoplatinum Compounds
- Oxaliplatin
- Deoxycytidine
- Capecitabine
- Glutathione S-Transferase pi
- Fluorouracil
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Capecitabine
- Codon
- Colorectal Neoplasms
(drug therapy, genetics)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Epidemiologic Methods
- Female
- Fluorouracil
(administration & dosage, analogs & derivatives)
- Genetic Predisposition to Disease
- Genotype
- Glutathione S-Transferase pi
(genetics)
- Humans
- Male
- Middle Aged
- Neurotoxicity Syndromes
(etiology, genetics)
- Organoplatinum Compounds
(administration & dosage, adverse effects)
- Oxaliplatin
- Polymorphism, Genetic
- Treatment Outcome
|